Gober Margaret, Hillier Andrew, Vasquez-Hidalgo Manuel A, Amodie Deborah, Mellencamp Martha A
Zoetis, Inc., Parsippany, NJ, United States.
Department of Animal Sciences, North Dakota State University, Fargo, ND, United States.
Front Vet Sci. 2022 Jul 19;9:909776. doi: 10.3389/fvets.2022.909776. eCollection 2022.
Allergic dermatitis is the most common type of skin disease in dogs. Of all dogs, 20 to 30% present with some type of allergic dermatitis. Pruritus is one of the most important signs of allergic dermatitis and is often the most challenging to control. Interleukin-31 (IL-31) has been found to be one of the main initiators of pruritus in dogs with allergic dermatitis. Cytopoint®, a caninized monoclonal anti-IL-31 antibody, has been shown to be effective for the treatment of dogs against allergic dermatitis and atopic dermatitis. US label indication. A recent retrospective study reported that Cytopoint achieved treatment success in 87.8% of the cases with allergic dermatitis. No prospective cohort studies have been performed investigating the effects of Cytopoint in dogs with allergic dermatitis using the dosing protocol prescribed on the product label in the United States. In this study, our objectives were to assess the efficacy of Cytopoint for treatment of canine allergic dermatitis of variable etiologies and management of the associated pruritus, and add to the body of evidence available to the veterinarian as they make treatment recommendations. Dogs included in this study had moderate to severe pruritus according to the Pruritus Visual Analog Scale (PVAS; ≥ 50 mm) and a history of likely continuation of pruritus at the time of presentation. On day 0, investigators recorded the initial body weight and every patient received one dose of Cytopoint (minimum 2 mg/kg SQ) and an isoxazoline product for parasite control. Treatment success for this study was defined as a ≥20 mm reduction in PVAS from Day 0. On Day 7, 94% of the dogs had achieved treatment success. On Day 28, 98% had achieved treatment success and cumulatively by day 56, 100% of the dogs achieved treatment success. This prospective study provides evidence that Cytopoint effectively treats dogs with allergic dermatitis of different types and the associated pruritus.
过敏性皮炎是犬类最常见的皮肤病类型。在所有犬只中，20%至30%患有某种类型的过敏性皮炎。瘙痒是过敏性皮炎最重要的症状之一，也是最难控制的症状之一。白细胞介素-31（IL-31）已被发现是患有过敏性皮炎犬只瘙痒的主要引发因素之一。Cytopoint®是一种犬源化单克隆抗IL-31抗体，已被证明对治疗犬类过敏性皮炎和特应性皮炎有效。美国标签适应症。最近一项回顾性研究报告称，Cytopoint在87.8%的过敏性皮炎病例中取得了治疗成功。尚未进行前瞻性队列研究，以按照美国产品标签规定的给药方案研究Cytopoint对患有过敏性皮炎犬只的影响。在本研究中，我们的目标是评估Cytopoint治疗不同病因犬类过敏性皮炎及控制相关瘙痒的疗效，并为兽医在提出治疗建议时增加可用的证据。根据瘙痒视觉模拟量表（PVAS；≥50毫米），本研究纳入的犬只患有中度至重度瘙痒，且在就诊时可能持续瘙痒。在第0天，研究人员记录初始体重，每只犬只接受一剂Cytopoint（最小剂量2毫克/千克皮下注射）和一种异恶唑啉产品用于寄生虫控制。本研究的治疗成功定义为与第0天相比PVAS降低≥20毫米。在第7天，94%的犬只取得了治疗成功。在第28天，98%的犬只取得了治疗成功，到第56天累计有100%的犬只取得了治疗成功。这项前瞻性研究提供了证据，证明Cytopoint能有效治疗不同类型的犬类过敏性皮炎及相关瘙痒。
